

HemoGenyx Pharmaceuticals

01:36 31 May 2018

Hemogenyx Pharmaceuticals chief hails a year of significant progress

HemoGenyx Pharmaceuticals PLC (LON:HEMO) chief executive Dr Vladislav Sandler described 2017 as a "significant year" after the company listed on the market and inked a collaboration with Oxford University.

But perhaps the most exciting development occurred after the period-end as the company was able to show that its CDX antibodies can attack and eliminate acute myelogenous leukaemia.

While the data emanated from a pre-clinical study, it was nevertheless encouraging.

In Monday's full-year results statement, shareholders were told work is "progressing successfully" towards the goal of submitting an investigational new drug application to the US Food and Drug Administration for its CDX antibodies product.

Lake Pharma deal

During the 12 months ended December 31, the company appointed Lake Pharma supplier of CDX antibodies, while the tie-up with Oxford University will help accelerate development of Hemogenyx's blood cancer treatments.

"2017 was a significant year for Hemogenyx as we successfully listed the business on the London Stock Exchange and raised the financing necessary to further develop novel therapies with the potential to transform the lives of bone marrow transplant patients," said CEO Sandler.

"We remain on track in the development of both of our products according to the timescale we outlined to investors in October. We continue to successfully develop our Hu-PHEC cell therapy product and we are on course to have our CDX antibodies product in readiness for the start of phase I trials as planned."

In common with companies at this formative stage of development Hemogenyx was loss-making. The deficit was £2.32m. The company was sitting on just under £1.9m of cash at the period-end.

Price: 10.1

Market Cap: £43.8 m

1 Year Share Price Graph



September 2019 March 2020 September 2020

Share Information

Code: HEMO

Listing: LSE

52 week High Low
15.4 0.95

Sector: Investments and investor services

Website: www.hemogenyx.com

Company Synopsis:

HemoGenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state-of-the-art research facility ("HemoGenyx"). For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).